Geneva (Reuters) - Johnson & Johnson could obtain late-stage trial results of a COVID-19 vaccine it is developing earlier than expected, with the company targeting January, its chief scientist, Paul Stoffels, said on Tuesday.
The U.S. company last month said it was hoping to have all the data needed to seek U.S. authorisation by February or earlier.
J&J’s candidate is a single-dose vaccine, whereas the vaccines from Moderna and Pfizer and another under development by AstraZeneca all require two shots several weeks apart.
Reporting by Stephanie Nebehay in Geneva, John Miller in Zurich and Matthias Blamont in Paris; Editing by David Goodman
Our Standards: The Thomson Reuters Trust Principles.